Max Shub OAM award.
February meeting speaker: Michelle Wells from Advance Care Planning Australia.
Clinical trial of the combination of a noninvasive, high precision radiotherapy technique SABR, with a monoclonal antibody Avelumab which works against a protein called PD1 on the surface of cancer cells. You may be eligible if you have been diagnosed with metastatic castration-resistant prostate cancer, and have a predicted life expactancy of at least 6 months.
A laboratory study designed antibodies which blocked fatty acids from entering cancer cells and reduced their growth by 90%. The ultimate goal is to combine this fatty acid therapy with existing treatments such as chemotherapy and radiotherapy at lower doses, to kill the cancer and reduce side effects.